Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone M. Yusoff Dawood, M.D.,

Slides:

Advertisements

Similar presentations

Age at menarche: a predictor of diminished ovarian function?

Advertisements

Impact of endogenous luteinizing hormone serum levels on progesterone elevation on the day of human chorionic gonadotropin administration Jean-noêl Hugues,

Akanksha Mehta, M.D., Mark Sigman, M.D. Fertility and Sterility

The relative effects of hormones and relationship factors on sexual function of women through the natural menopausal transition Lorraine Dennerstein,

Can pregnancy rate be improved in gonadotropin-releasing hormone (GnRH) antagonist cycles by administering GnRH agonist before oocyte retrieval? A prospective,

Fernando Zegers-Hochschild, M.D. Fertility and Sterility

Triggering with human chorionic gonadotropin or a gonadotropin-releasing hormone agonist in gonadotropin-releasing hormone antagonist-treated oocyte donor.

1,500 IU human chorionic gonadotropin administered at oocyte retrieval rescues the luteal phase when gonadotropin-releasing hormone agonist is used for.

Ovarian stimulation to cryopreserve fertilized oocytes in cancer patients can be started in the luteal phase Michael von Wolff, M.D., Christian J. Thaler,

Michael M. Alper, M.D. Fertility and Sterility

Adherence compounds in embryo transfer media for assisted reproductive technologies: summary of a Cochrane review Stephan Bontekoe, M.D., Neil Johnson,

2-Methoxyestradiol in the human corpus luteum throughout the luteal phase and its influence on lutein cell steroidogenesis and angiogenic activity Paulina.

The luteal phase of recombinant follicle-stimulating hormone/gonadotropin-releasing hormone antagonist in vitro fertilization cycles during supplementation.

Can an educational DVD improve the acceptability of elective single embryo transfer? A randomized controlled study Nicole Hope, M.B., B.S., Hon., Luk.

Cutoff value of human chorionic gonadotropin in relation to the number of methotrexate cycles in the successful treatment of ectopic pregnancy Ewa Nowak-Markwitz,

Medical treatment of ectopic pregnancy: a committee opinion

Hakan Cakmak, M. D. , Audra Katz, R. N. , Marcelle I. Cedars, M. D

Grant D.E. McWilliams, D.O., John L. Frattarelli, M.D.

How old is too old? Challenges faced by clinicians concerning age cutoffs for patients undergoing in vitro fertilization Robert L. Klitzman, M.D. Fertility.

The role of steroid hormone supplementation in non–assisted reproductive technology treatments for unexplained infertility Alexander M. Quaas, M.D.,

Improved monofollicular ovulation in anovulatory or oligo-ovulatory women after a low- dose step-up protocol with weekly increments of 25 international.

Subtle progesterone rise on the day of human chorionic gonadotropin administration is associated with lower live birth rates in women undergoing assisted.

Association of a single dose of gonadotropin-releasing hormone antagonist with nitric oxide and embryo quality in in vitro fertilization cycles Tsung-Hsien.

Oocyte cryopreservation

Robert F. Casper, M.D. Fertility and Sterility

Mieke Carine Wim Eeckhaut, Ph.D. Fertility and Sterility

Looking back: egg donors' retrospective evaluations of their motivations, expectations, and experiences during their first donation cycle Nancy J. Kenney,

Impact of luteal phase support on pregnancy rates in intrauterine insemination cycles: a prospective randomized study Ahmet Erdem, M.D., Mehmet Erdem,

Influence of acupuncture stimulation on pregnancy rates for women undergoing embryo transfer Caroline Smith, Ph.D., Meaghan Coyle, B.Hlth.Sc. (Acup.),

Rahi Victory, M. D. , F. R. C. S. C. , Ghassan M. Saed, Ph. D

Estrogens and androgens affect human luteal cell function

Association between prior appendectomy and/or tonsillectomy in women and subsequent pregnancy rate: a cohort study Li Wei, Ph.D., Thomas MacDonald, M.D.,

Amir M. Khan, M. D. , Sunit Jariwala, M. D. , Harry Jay Lieman, M. D

Ultrashort flare gonadotropin-releasing hormone (GnRH) agonist/GnRH antagonist protocol: a valuable tool in the armamentarium of ovulation induction for.

A meta-analysis of the route of administration of luteal phase support in assisted reproductive technology: vaginal versus intramuscular progesterone

Comparison of luteal estradiol patch and gonadotropin-releasing hormone antagonist suppression protocol before gonadotropin stimulation versus microdose.

Management of tubal ectopic pregnancy: methotrexate and salpingostomy are preferred to preserve fertility Stephanie Beall, M.D., Ph.D., Alan H. DeCherney,

Clomiphene citrate at 50: the dawning of assisted reproduction

Maternal complication of cervical heterotopic pregnancy after successful potassium chloride fetal reduction Cynthia Gyamfi, M.D., Samantha Cohen, B.A.,

Treatment of Ovarian Hyperstimulation Syndrome Utilizing a Dopamine Agonist and Gonadotropin Releasing Hormone antagonist N. Rollene, M. Amols, S. Hudson,

Introduction Fertility and Sterility

Akanksha Mehta, M.D., Darius A. Paduch, M.D., Ph.D.

Changes in cytokine levels of patients with ovarian endometriosis after treatment with gonadotropin-releasing hormone analogue, ultrasound-guided drainage,

Increased secretion of amylin in women with polycystic ovary syndrome

Clinical and endocrine response to the withdrawal of gonadotropin-releasing hormone agonists during prolonged coasting Basil Ho Yuen, M.B., Ch.B., Tuan-Anh.

GnRH antagonists may affect endometrial receptivity

P-425 Fertility and Sterility Volume 86, Issue 3, (September 2006)

Cameron Gilbert, M. Sc. , Maria Valois, M. D. , FRCPC, Ph. D

Website quality assessment: Mistaking apples for oranges

Effects of growth hormone and insulin-like growth factor 1 on progesterone production in human luteinized granulosa cells Toshiaki Taketani, M.D., Yoshiaki.

Pregnancy outcome in infertile patients with polycystic ovary syndrome who were treated with metformin Samuel S. Thatcher, M.D., Ph.D., Elizabeth M.

Effects of hyperglycemia on the differential expression of insulin and insulin-like growth factor-I receptors in human normal peritoneal and adhesion.

Human granulosa-lutein cell in vitro production of progesterone, inhibin A, inhibin B, and activin A are dependent on follicular size and not the presence.

L. Scott, J. Bernsten, K. DeLegge, J. Hill, N. Ramsing

Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization David W. Schmidt, M.D.,,

Fertility and Sterility: an evaluation

Vaginal micronized progesterone versus intramuscular progesterone for luteal support in women undergoing in vitro fertilization–embryo transfer Mohamed.

Upregulation of mRNA expression of vascular endothelial growth factor and its receptors by exogenous human chorionic gonadotropin in cultured oviduct.

Adenomyosis in the baboon is associated with primary infertility

Current evaluation of amenorrhea

In vitro sildenafil citrate use as a sperm motility stimulant

Soluble HLA-G in the peritoneal fluid of women with endometriosis

Progesterone level and progesterone/estradiol ratio on the day of hCG administration: detrimental cutoff levels and new treatment strategy Eman A. Elgindy,

Ongoing pregnancy rates in intrauterine insemination are affected by late follicular- phase progesterone levels Antonio Requena, M.D., María Cruz, Ph.D.,

A randomized controlled trial of increasing recombinant follicle-stimulating hormone after initiating a gonadotropin-releasing hormone antagonist for.

Endometrial polyps affect uterine receptivity

Ovarian hyperstimulation syndrome prevention by gonadotropin-releasing hormone agonist triggering of final oocyte maturation in a gonadotropin-releasing.

In vitro viability and secretory capacity of human luteinized granulosa cells after gonadotropin-releasing hormone agonist trigger of oocyte maturation

Tamer M. Said, M. D. , Geetha Ranga, M. D. , Ashok Agarwal, Ph. D. , H

P-24 Fertility and Sterility Volume 85, Pages S19-S20 (April 2006)

Presentation transcript:

Effect of the oxytocin antagonist antocin and agonist decomoton on baboon luteal cell production and release of progesterone M. Yusoff Dawood, M.D., Firyal S. Khan-Dawood, Ph.D. Fertility and Sterility Volume 90, Issue 4, Pages 1366-1371 (October 2008) DOI: 10.1016/j.fertnstert.2007.08.045 Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 1 Effect of oxytocin (mU), oxytocin antagonist antocin (μg), and antocin combined with oxytocin on mean ± standard error of the mean (SEM) luteal cell basal P secretion. P secretion without addition of any peptide has been normalized to 100% (expressed as no change or 0%) and changes are calculated against this with a reduction expressed as −% and an increase as +%. There was no significant change in P secretion with all peptides and doses used. OT = oxytocin; ANT = antocin. Fertility and Sterility 2008 90, 1366-1371DOI: (10.1016/j.fertnstert.2007.08.045) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 2 Effect of oxytocin (mU), oxytocin antagonist antocin (μg), and antocin combined with oxytocin on mean ± standard error of the mean (SEM) luteal cell hCG-stimulated P secretion. For stimulation, 10 IU hCG was used. P secretion without addition of any peptide has been normalized to 100% (expressed as no change or 0%) and changes are calculated against this with a reduction expressed as −% and an increase as +%. Changes in P secretion were significantly inhibited (∗P≤.05) with all peptides and doses used. OT = oxytocin; ANT = antocin. Fertility and Sterility 2008 90, 1366-1371DOI: (10.1016/j.fertnstert.2007.08.045) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 3 Effect of oxytocin (mU), oxytocin agonist decomoton (μg), and decomoton combined with oxytocin on mean ± standard error of the mean (SEM) luteal cell basal P secretion. P secretion without addition of any peptide has been normalized to 100% (expressed as no change or 0%) and changes are calculated against this with a reduction expressed as −% and an increase as +%. There was no significant change in P secretion with all peptides and doses used. OT = oxytocin; D = decomoton. Fertility and Sterility 2008 90, 1366-1371DOI: (10.1016/j.fertnstert.2007.08.045) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions

Figure 4 Effect of oxytocin (mU), oxytocin agonist decomoton (μg), and decomoton combined with oxytocin on mean ± standard error of the mean (SEM) luteal cell hCG-stimulated P secretion. For stimulation, 10 IU hCG was used. P secretion without addition of any peptide has been normalized to 100% (expressed as no change or 0%) and changes are calculated against this with a reduction expressed as −% and an increase as +%. Changes in P secretion were significantly inhibited (∗P≤.05) with all peptides and doses used. OT = oxytocin; D = decomoton. Fertility and Sterility 2008 90, 1366-1371DOI: (10.1016/j.fertnstert.2007.08.045) Copyright © 2008 American Society for Reproductive Medicine Terms and Conditions